http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008014596-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d2885cfb3e5d4a4eb3b3088022fbde8a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_579018e98da47580942af6de9e380c1c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4709 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5058 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate | 2006-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e741f42d4c58927734dd0b7e1f01c505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f386559ac9146935dae82875104e71f |
| publicationDate | 2008-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2008014596-A1 |
| titleOfInvention | ADDL Binding to Hippocampal Neurons |
| abstract | Disclosed herein are methods for the quantification of ADDL binding to neuronal cells, including, but not limited to, primary cultures of hippocampal neurons. The method identifies and selects neurons based on any means capable of distinguishing neuronal cells, including, but not limited to, MAP2 immunoreactivity, which ensures that glial cells are excluded from an ADDL binding analysis; antibodies selective for neuronal cell surface receptors and/or other surface markers; reagents specific for neuronal signalling markers present intracellularly; and the like. Furthermore, ADDL binding occurs in a sub-population of 16 DIV neurons and is heterogeneous in intensity among individual cells. Also, ADDL binding can be further specified and quantified by using additional markers. Additionally, the presence or absence of ADDL binding is used to identify, characterize, analyze, assess, and/or evaluate agents (e.g., including, but not limited to, small molecules, antibodies, chemical compounds, dietary components, environmental conditions, etc.) that modulate ADDL binding. Such modulation can be positive or negative, including, but not limited to, ADDL binding inhibition, either total inhibition or partial inhibition, and the like. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10538581-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9822171-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9394360-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9951125-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9540432-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10464976-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10047121-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10323084-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015079096-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9359430-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10208109-B2 |
| priorityDate | 2005-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.